Meng-Yao Qin

Molecular subgroups and biomarker guided precision immunotherapy in triple-negative breast cancer: advances, challenges, and future directions

Triple-negative breast cancer is an aggressive, biologically heterogeneous subtype with limited targeted therapies. Immunotherapy improves outcomes in selected patients, but durable benefit is limited by inter- and intratumoral heterogeneity, imperfect biomarkers, and primary or acquired resistance. This review integra...